Nanobiotix shares rise 2.5%, driven by a 35% gain over one month

A 2.44% rebound that puts Nanobiotix back at the top of the SBF 120

Nanobiotix shares gain 2.44% to €27.66 intraday, compared with €27 at the last close, while the SBF 120 rises 0.37%. The stock is among the index's strongest gainers, behind Valneva, Mersen, SES and Genfit. It nevertheless falls 1.64% over one week, but remains up 34.8% over one month.

The share price is above the MM20 moving average (a gap of +10.42%) and the MM50 moving average (+1.92%), reflecting the recovery under way since late October. However, it remains below the MM200 moving average, located at €29.52 (a gap of -6.30%). The RSI at 55 is neutral.

By way of comparison, Sanofi, a stock in the same sector, gains 2.38% this Monday. Nanobiotix is listed both in Paris and on the Nasdaq (ADS NBTX, at a ratio of one ADS per share): the US line closed up more than one point on Friday for the Nasdaq index.

A financing runway into 2029 following the first-half results

When it published its H1 2026 results on September 24, the company stated that its cash position of €110.9 million enables it to finance its operations until 2029. It also believes it has sufficient liquidity to meet its obligations for at least the next twelve months.

On the clinical front, Nanobiotix presented on October 24, at the ESMO congress in Madrid, the results of the melanoma cohort of its Phase 1 study, with a median overall survival of 17.8 months among 24 patients resistant to anti-PD-1 therapies.

From a technical standpoint, resistance is at €30.36 and support at €18.85. The price of €27.66 remains below resistance, in an area where the stock had already traded in late October.